In Vitro Characterization and Stability Profiles of Antibody–Fluorophore Conjugates Derived from Interchain Cysteine Cross-Linking or Lysine Bioconjugation

Archive ouverte

Martin, Camille | Brachet, Guillaume | Colas, Cyril | Allard-Vannier, Emilie | Kizlik-Masson, Claire | Esnault, Clara | Respaud, Renaud | Denevault-Sabourin, Caroline | Chourpa, Igor | Gouilleux-Gruart, Valérie | Viaud-Massuard, Marie-Claude | Joubert, Nicolas

Edité par CCSD ; MDPI -

International audience. Fluorescent labelling of monoclonal antibodies (mAbs) is classically performed by chemical bioconjugation methods. The most frequent labelling technique to generate antibody-fluorophore conjugates (AFCs) involves the bioconjugation onto the mAb lysines of a dye bearing an N-hydroxysuccinimide ester or an isothiocyanate group. However, discrepancies between labelling experiments or kits can be observed, related to reproducibility issues, alteration of antigen binding, or mAb properties. The lack of information on labelling kits and the incomplete characterization of the obtained labelled mAbs largely contribute to these issues. In this work, we generated eight AFCs through either lysine or interchain cysteine cross-linking bioconjugation of green-emitting fluorophores (fluorescein or BODIPY) onto either trastuzumab or rituximab. This strategy allowed us to study the influence of fluorophore solubility, bioconjugation technology, and antibody nature on two known labelling procedures. The structures of these AFCs were thoroughly analyzed by mass spectroscopy, and their antigen binding properties were studied. We then compared these AFCs in vitro by studying their respective spectral properties and stabilities. The shelf stability profiles and sensibility to pH variation of these AFCs prove to be dye-, antibody- and labelling-technology-dependent. Fluorescence emission in AFCs was higher when lysine labelling was used, but cross-linked AFCs were revealed to be more stable. This must be taken into account for the design of any biological study involving antibody labelling.

Suggestions

Du même auteur

Site-specific conjugation of auristatins onto engineered antibody fragments to target her2-positive breast cancer in vitro

Archive ouverte | Ait Mohamed Amar, Imène | CCSD

poster + "pitch" de présentation du poster de 90sposter + "pitch" de présentation du poster de 90s. The combination of a highly potent cytotoxic agent (drug) with a specific therapeutic monoclonal antibody (mAb) via...

Increment in Drug Loading on an Antibody–Drug Conjugate Increases Its Binding to the Human Neonatal Fc Receptor in Vitro

Archive ouverte | Brachet, Guillaume | CCSD

International audience. Antibody-drug conjugates, such as brentuximab vedotin (BTXv), are an innovative category of monoclonal antibodies. BTXv is bioconjugated via the chemical reduction of cysteine residues involv...

Impact of cathepsin B-sensitive triggers and hydrophilic linkers on in vitro efficacy of novel site-specific antibody–drug conjugates

Archive ouverte | Bryden, Francesca | CCSD

International audience

Chargement des enrichissements...